الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 150 |  |  |
| | | from | 150 | | |
Abstract
E
ndometrial cancer (EC) is the fourth most common malignancy in women and the most common gynecologic cancer in developed countries, with an overall incidence of 7% and 63,230 estimated new cases.
EC cells have the ability to activate programmed death-1 (PD-1) signaling, by overexpressing PD-L1 and PDL-2, which can bind PD-1 receptors, expressed on tumor-infiltrating CD4 and CD8 T cells and inactivates them in the tumor microenvironment.
EC cells overexpress PD-1 (present in 75% of cases) and PD-L1 (in 25%–100% of cases) the most among gynecological cancer. For this reason, targeting this pathway seems a promising strategy to enhance antitumor immune response.
As concluded by Kim and colleagues, PD-L1 expression in endometrial cancer cells correlates with postmenopausal status, high histological grade (grade 3), deep myometrial invasion (≥1/2), lymphovascular invasion, adjuvant therapy, and MSI status.
This retrospective study was conducted at Ain Shams University Maternity Hospital and early cancer detection unit in the period between December 2019 to January 2021 (COVID-19 is pandemic).
The participants of this study were 38 women diagnosed as high grade endometrial carcinoma in the period from January 2014 till December 2018 with full medical records in Ain Shams University Oncology Hospital and in Early Cancer Detection Unit (ECDU) at Ain Shams University Hospital (ASUH). Women with inadequate paraffin blocks, non-histologically proven endometrial neoplasm and/or with unavailable follow up data were excluded from the study. Patients’ paraffin blocks were collected and tested for PDL1 expression using immunohistochemistry test (IHC) for detection of PDL1 proteins.
Statistical analysis of current study stated that PD-1 and PD-L1 expressions cannot be used as prognostic factors in this disease. Our results reported PD-L1 expression in 44.7% (n: 17) versus 55.3% (n: 21) without expression and PD-L1 TIL expression in 28.9% (n: 11) versus 71.1% (n: 27) without expression with no statistical significant relation. There was no correlation between PD-L1 and PD-L1 TIL expression and event free survival time and overall survival time. There was no correlation between PD-L1 and PD-L1 TIL expression and clinico-pathological criteria of the tumor